Fig. 1From: Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel diseaseClinical activity scores using the short paediatric Crohn’s disease activity index (shPCDAI) in the CD cohort (a) and the paediatric ulcerative colitis activity index (PUCAI) in the UC cohort (b). The dots indicate observations, which exceed the third quartile (i.e., the upper boundary of the box) by more than 1.5 times the interquartile rangeBack to article page